Dr. Carruthers Joins Htg As Vp Target Strategy And Early...
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Dr. Carruthers Joins Htg As Vp Target Strategy And Early Development, Therapeutics Division

Pharma Tech Outlook | Friday, April 15, 2022

By leveraging the capability of transcriptome-wide profiling to promote translational research, clinical diagnostics, and tailored medicines across a number of disease categories, HTG is expediting precision medicine from diagnosis to treatment.

FREMONT, CA: New therapeutic approaches grounded in RNA either as target or modality have the potential to reform our thinking on how to understand and ultimately treat diseases. I believe HTGs proprietary technologies will undoubtedly play a key role in this area of scientific advancement and Im very excited to become a member of this dynamic team," said Dr. Carruthers.

HTG Molecular Diagnostics, Inc., a life science company that uses innovative transcriptome-wide profiling technology to advance precision medicine, has declared the addition of Christina M. Carruthers, Ph.D., an experienced program leader in drug discovery and development, to its therapeutics team. Dr. Carruthers joins HTG as Vice President of Target Strategy and Early Development, a critical role in the Therapeutics Division.

"Dr. Carruthers has an extensive background in the pharmaceutical and biotech industries, with her experiences spanning drug discovery, early development, registration and due diligence supporting pipeline development through partnerships and acquisitions," said Dr. Stephen A. Barat, Senior Vice President of Therapeutics at HTG. "This well-rounded experience will be invaluable as we continue to leverage our proprietary RNA platform in our efforts to disrupt the traditional drug discovery process and bring innovative small molecule therapeutic candidates forward."

Dr. Carruthers most recently worked for Moderna Therapeutics as the Scientific Director and Research Area Leader for Rare Diseases. He oversaw nonclinical strategy, data assessment, and scientific communications for many programs. She formerly worked at Janssen Research & Development as a Scientific Director. She oversaw the discovery and early-development initiatives in various therapeutic areas and modalities, ranging from small molecules to RNA. In addition, she worked at Scynexis as the Director of Preclinical Development and Operations and at Allergan, Inc. and Covance Laboratories in various scientific capacities. She received her bachelor's degree from Central Connecticut State University and her doctorate from Bowling Green State University before joining the National Institute of Environmental Health Sciences as a Postdoctoral Fellow in Reproductive and Developmental Biology.

Weekly Brief

Read Also